SpringWorks Therapeutics
Focus: SpringWorks Therapeutics is a mid-cap oncology-focused biotech company developing small-molecule inhibitors for rare and underserved tumor types. The company has achieved commercial validation with OGSIVEO (nirogacestat) across desmoid fibromatosis, multiple myeloma, and ovarian granulosa cell tumors.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
9+2 this month
Stable — net +2 jobs in 30d
6 added, 4 removed. Backfill posture.
Should You Work at SpringWorks Therapeutics?
AI assessmentSpringWorks is a viable mid-stage biotech with commercial traction but carries concentrated revenue risk; best suited for professionals seeking rare disease exposure and commercial-stage growth, but with heightened career stability concerns.
Why Work Here
- Commercial-stage biotech with FDA-approved product generating revenue and 20+ active clinical programs across oncology indications
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$429K Part DGrowing
Growth
Help build intelligence for SpringWorks Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.